To meet the demands of the international pharmaceutical industry, Laurus Labs primarily provides a comprehensive and integrated portfolio of Active Pharmaceutical Ingredients (API), including intermediates, Generic Finished Dosage Forms (FDF), and Contract Research services.
Financial Results:
- Laurus Labs Ltd. reported Total Income for Q4FY23 of ₹ 1,382.61 Crores down from ₹ 1,426.12 Crore year on year, a fall of 3%.
- Total Expenses for Q4FY23 of ₹ 1,235.47 Crores up from ₹ 1,124.41 Crores year on year, a rise of 10%.
- Consolidated Net Profit of ₹ 107.24 Crores, down 54% from ₹ 231.90 Crores in the same quarter of the previous year.
- The Earnings per Share is ₹ 1.90, down 56% from ₹ 4.28 in the same quarter of the previous year.